Theravance Biopharma Inc share price logo

Theravance Biopharma Inc

NASDAQ: TBPH

Small Cap

$16.34

-0.21

(-1.27%)

as on

Theravance Biopharma Inc Stock Performance

as on May 22, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $16.32
    $16.59
    downward going graph

    0.12%

    Downside

    1.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.10
    $21.03
    downward going graph

    44.31%

    Downside

    28.70%

    Upside

    downward going graph

Theravance Biopharma Inc share price movements today

Previous Close
$16.55
Open
$16.46
Volume
239.0K
Day's Low - High
$16.32 - $16.59
52 Week Low - High
$9.10 - $21.03

Theravance Biopharma Inc Historical Returns

1 Month Return
-1.39 %
3 Month Return
-16.89 %
1 Year Return
+ 72.18 %
3 Year Return
+ 48.95 %
5 Year Return
-6.31 %

Theravance Biopharma Inc Stock Fundamentals & Key Indicators

Check Theravance Biopharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$853.2M

EPS (TTM)

0.21

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

7.42

Industry PE ratio

-3.8304185022026433

PEG Ratio

-0.05

EBITDA

6.6M

Revenue (TTM)

109.8M

Profit Margin

104.34%

Return On Equity TTM

50.17%

Theravance Biopharma Inc Stock Valuation

Track how Theravance Biopharma Inc P/E has moved over time to understand its valuation trends.

Theravance Biopharma Inc in the last 5 years

  • Overview

  • Trends

Lowest (-128.99x)

December 31, 2025

Industry (-3.83x)

May 22, 2026

Today (7.42x)

May 22, 2026

Highest (-2.95x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: 7.42x

Theravance Biopharma Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Theravance Biopharma Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Theravance Biopharma Inc image
Theravance Biopharma Inc
BUY$853.2M-6.31%7.42104.34%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.9B114.56%75.1812.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.2B103.13%25.5835.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$68.1B26.81%15.8729.65%

Stock Returns calculator for Theravance Biopharma Inc Stock including INR - Dollar returns

The Theravance Biopharma Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Theravance Biopharma Inc investment value today

Current value as on today

₹1,93,483

Returns

₹93,483

(+93.48%)

Returns from Theravance Biopharma Inc Stock

₹72,181 (+72.18%)

Dollar Impact

₹21,301 (+21.3%)

Analyst Recommendation on Theravance Biopharma Inc Stock

Based on 11 analysts

BUY

72.73%

Buy

27.27%

Hold

0.00%

Sell

Based on 11 analysts, 72.73% of analysts recommend a 'BUY' rating for Theravance Biopharma Inc. Average target price of $17.2

Theravance Biopharma Inc Share Price Target

Get share price movements and forecasts by analysts on Theravance Biopharma Inc.

What analysts predicted

5%UPSIDE

Target Price

$17.2

Current Price

$16.34

Analyzed by

11 Analysts

Target

$17.20

Theravance Biopharma Inc target price $17.2, a slight upside of 5% compared to current price of $16.34. According to 11 analysts rating.

Indian Investors' Interest in Theravance Biopharma Inc Stock

Search interest for Theravance Biopharma Inc Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-48% versus previous 30 day period

Theravance Biopharma Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
17
14
14
16
18
15
26
19
45
17
Gross Profit
9
5
4
7
18
3
15
11
44
16
Operating Income
-6
-11
-15
-10
-9
-14
-2
-6
17
-8
EBITDA
-6
-10
-12
-8
-7
-14
-2
-1
19
-6
Interest Expense
0
0
0
0
0
0
0
0
0
-
Depreciation
1
1
0
0
0
1
0
0
0
0
Income Before Tax
-5
-10
-15
-10
-8
-14
73
-2
73
-6
Income Tax Expense
3
1
1
2
6
0
18
-6
12
-1
Net Income
-8
-11
-16
-12
-15
-13
54
3
61
-4
Net Profit Margin
-48.45%
-80.42%
-115.94%
-75.28%
-82.79%
-88.24%
209.33%
18.08%
132.98%
-27.87%

Theravance Biopharma Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
48
15
60
73
71
55
51
57
64
107
Gross Profit
45
9
59
73
71
-138
-12
16
64
101
Operating Income
-180
-260
-238
-251
-297
-257
-91
-56
-46
-13
EBITDA
-176
-259
-212
-203
-287
-232
-76
-51
-38
-7
Interest Expense
1
8
10
31
8
8
6
2
2
2
Depreciation
-
4
3
6
9
9
7
4
3
2
Income Before Tax
-180
-271
-226
-241
-303
-265
-92
-49
-44
129
Income Tax Expense
10
13
-10
-5
-8
0
0
5
11
23
Net Income
-190
-285
-215
-236
-278
-199
872
-55
-56
105
Net Profit Margin
-391.94%
-1854.97%
-357.01%
-322.08%
-386.90%
-360.55%
1698.54%
-96.11%
-87.63%
98.54%

Theravance Biopharma Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-11
-16
-12
-15
-13
54
3
61
-4
Operating Cash Flow
-1
-4
-5
0
43
208
-6
-6
73
Investing Cash Flow
17
-3
-17
15
30
-36
-100
0
52
Financing Cash Flow
-1
0
0
0
0
0
0
-1
-5
Change in Cash
14
-7
-22
14
72
171
-107
-6
120

Theravance Biopharma Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-285
-215
-236
-278
-265
-92
-55
-56
105
Operating Cash Flow
-201
-112
-238
-250
-207
-186
-26
-11
238
Investing Cash Flow
-56
176
-83
10
124
1,154
-32
12
-105
Financing Cash Flow
1
225
1
263
91
-758
-198
-2
-3
Change in Cash
-255
289
-319
23
8
208
-258
-1
130

Global Institutional Holdings in Theravance Biopharma Inc

Funds
Holdings
Morgan Stanley - Brokerage Accounts
1.56%
HHG PLC
0.78%
Park West Asset Management LLC
3.57%
Oasis Management Co. Ltd
1.41%
Citadel Advisors Llc
0.96%
See all

Theravance Biopharma Inc News & Key Events

    Insights on Theravance Biopharma Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 year, TBPH stock has moved up by 72.2%

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, TBPH has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, TBPH has outperformed top 5 stocks with highest market-cap in its industry

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 61.02M → -4.93M (in $), with an average decrease of 108.1% per quarter

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 45.89M → 17.69M (in $), with an average decrease of 61.4% per quarter

    About Theravance Biopharma Inc

    Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
    OrganisationTheravance Biopharma Inc
    Headquarters901 Gateway Boulevard, South San Francisco, CA, United States, 94080
    IndustryBiotechnology
    CEOMr. Rick E. Winningham M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Theravance Biopharma Inc

    Name

    Title

    Dr. Aine Miller Ph.D.

    Senior VP of Development & Head of Ireland Office

    Mr. Aziz Sawaf C.F.A.

    Senior VP & CFO

    Mr. Stuart Knight

    Senior VP of IT&I and Chief Information Officer

    Mr. Brett A. Grimaud Esq.

    Senior VP, General Counsel & Secretary

    Ms. Stacy L. Pryce

    Senior VP & Chief Strategy Officer

    Mr. Rick E. Winningham M.B.A.

    CEO & Director

    Ms. Rhonda F. Farnum

    Chief Business Officer and Senior VP of Commercial & Medical Affairs

    FAQs

    What is Theravance Biopharma Inc share price today?

    Theravance Biopharma Inc share price today is $16.34 as on at the close of the market. Theravance Biopharma Inc share today touched a day high of $16.59 and a low of $16.32.

    What is the 52 week high and 52 week low for Theravance Biopharma Inc share?

    Theravance Biopharma Inc share touched a 52 week high of $21.03 on and a 52 week low of $9.1 on . Theravance Biopharma Inc stock price today i.e. is closed at $16.34,which is 22.30% down from its 52 week high and 79.56% up from its 52 week low.

    What is Theravance Biopharma Inc's market capitalisation today?

    Theravance Biopharma Inc market capitalisation is $0.00T as on .

    How to invest in Theravance Biopharma Inc Stock (TBPH) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Theravance Biopharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Theravance Biopharma Inc Shares that will get you 0.0918 shares as per Theravance Biopharma Inc share price of $16.34 per share as on May 22, 2026 at 8:45 am IST.

    What is the minimum amount required to buy Theravance Biopharma Inc Stock (TBPH) from India?

    Indian investors can start investing in Theravance Biopharma Inc (TBPH) shares with as little as ₹96.19 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹961.90 in Theravance Biopharma Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Theravance Biopharma Inc share’s latest price of $16.34 as on May 22, 2026 at 8:45 am IST, you will get 0.6120 shares of Theravance Biopharma Inc. Learn more about fractional shares .

    What are the returns that Theravance Biopharma Inc has given to Indian investors in the last 5 years?

    Theravance Biopharma Inc stock has given -6.31% share price returns and 32.3% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?